IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-56506-5.html
   My bibliography  Save this article

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction

Author

Listed:
  • Rui Liu

    (Xiamen University)

  • Zongwei Li

    (Anhui Medical University)

  • Rui Chen

    (Xiamen University)

  • Zhihong Fang

    (Xiamen University
    Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy)

  • Zhiqiang Liu

    (Shandong First Medical University and Shandong Academy of Medical Sciences)

  • Huan Liu

    (Xiamen University
    Xiamen University
    Xiamen University
    Shenzhen Research Institute of Xiamen University)

Abstract

Myelomatous bone disease is a complication characterized by lytic bone lesions, reduced bone formation, bone pain, and increased fracture risk. Understanding these underlying mechanisms is crucial for developing effective therapeutic approaches. Here we show the role of enhancer of zeste homolog 2 (EZH2) in bone lesions induced by myeloma cells. Our research reveals that cytokines produced by myeloma-associated adipocytes activate the expression of EZH2 in myeloma cells. Furthermore, we find that EZH2 forms a transcriptional repression complex with transcription factor AP2α. This complex promotes trimethylation at lysine 27 of histone H3 (H3K27me3) in the promoter region of the tumor suppressor gene EMP1, resulting in transcriptional silencing. EMP1 silencing leads to increased myeloma cell proliferation and the concomitant secretion of osteolytic cytokines that contribute to bone destruction. Importantly, EZH2 inhibitors effectively treat myeloma-induced osteolytic lesions. Thus, targeting EZH2 represents a potential therapeutic strategy for preventing and managing myeloma bone disease.

Suggested Citation

  • Rui Liu & Zongwei Li & Rui Chen & Zhihong Fang & Zhiqiang Liu & Huan Liu, 2025. "EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction," Nature Communications, Nature, vol. 16(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56506-5
    DOI: 10.1038/s41467-025-56506-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-56506-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-56506-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Dongjun Peng & Ilona Kryczek & Nisha Nagarsheth & Lili Zhao & Shuang Wei & Weimin Wang & Yuqing Sun & Ende Zhao & Linda Vatan & Wojciech Szeliga & Jan Kotarski & Rafał Tarkowski & Yali Dou & Kathleen , 2015. "Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy," Nature, Nature, vol. 527(7577), pages 249-253, November.
    2. Ji-Won Lee & Akiyoshi Hoshino & Kazuki Inoue & Takashi Saitou & Shunsuke Uehara & Yasuhiro Kobayashi & Satoshi Ueha & Kouji Matsushima & Akira Yamaguchi & Yuuki Imai & Tadahiro Iimura, 2017. "The HIV co-receptor CCR5 regulates osteoclast function," Nature Communications, Nature, vol. 8(1), pages 1-16, December.
    3. Huan Liu & Jin He & Rozita Bagheri-Yarmand & Zongwei Li & Rui Liu & Zhiming Wang & Duc-hiep Bach & Yung-hsing Huang & Pei Lin & Theresa A. Guise & Robert F. Gagel & Jing Yang, 2022. "Osteocyte CIITA aggravates osteolytic bone lesions in myeloma," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    4. Daniel Zingg & Julien Debbache & Simon M. Schaefer & Eylul Tuncer & Sandra C. Frommel & Phil Cheng & Natalia Arenas-Ramirez & Jessica Haeusel & Yudong Zhang & Mario Bonalli & Michael T. McCabe & Caret, 2015. "The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors," Nature Communications, Nature, vol. 6(1), pages 1-17, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dae Joong Kim & Swetha Anandh & Jamie L. Null & Piotr Przanowski & Sanchita Bhatnagar & Pankaj Kumar & Sarah E. Shelton & Erin E. Grundy & Katherine B. Chiappinelli & Roger D. Kamm & David A. Barbie &, 2023. "Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    2. Cang Li & Zhengyu Wang & Licheng Yao & Xingyu Lin & Yongping Jian & Yujia Li & Jie Zhang & Jingwei Shao & Phuc D. Tran & James R. Hagman & Meng Cao & Yusheng Cong & Hong-yu Li & Colin R. Goding & Zhi-, 2024. "Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    3. Jinbo Li & Zhenqiang Yao & Xin Liu & Rong Duan & Xiangjiao Yi & Akram Ayoub & James O. Sanders & Addisu Mesfin & Lianping Xing & Brendan F. Boyce, 2023. "TGFβ1+CCR5+ neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    4. Hanhan Ning & Shan Huang & Yang Lei & Renyong Zhi & Han Yan & Jiaxing Jin & Zhenyu Hu & Kaimin Guo & Jinhua Liu & Jie Yang & Zhe Liu & Yi Ba & Xin Gao & Deqing Hu, 2022. "Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity," Nature Communications, Nature, vol. 13(1), pages 1-20, December.
    5. Yousef Zakharia & Eric A. Singer & Satwik Acharyya & Rohan Garje & Monika Joshi & David Peace & Veera Baladandayuthapani & Annesha Majumdar & Xiong Li & Claudia Lalancette & Ilona Kryczek & Weiping Zo, 2024. "Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    6. Yazhong Cui & Yang Miao & Longzhi Cao & Lifang Guo & Yue Cui & Chuanzhe Yan & Zhi Zeng & Mo Xu & Ting Han, 2023. "Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity," Nature Communications, Nature, vol. 14(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-56506-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.